Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of a novel COVID-19 mRNA vaccine in adults
ChiCTR2100049104Phase 3Not yet recruiting
- Sponsor
- Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ARCoV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region. Primary endpoints: S-RBD specific IgG antibody seroconversion rate, S-RBD specific IgG geometric mean titer and 8 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
ARCoV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100049104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049104.